Innovent Doses First Participant in Pivotal Phase 3 Clinical Trial for IBI354 Targeting HER2-Positive Breast Cancer Innovent Biologics has announced the initiation of a Phase 3 trial to evaluate IBI354, a promising treatment for HER2-positive breast cancer, highlighting its potential efficacy and safety.

Innovent Doses First Participant in Pivotal Phase 3 Clinical Trial for IBI354 Targeting HER2-Positive Breast Cancer #China #Suzhou #HER2-positive #Innovent #IBI354

Innovent Biologics Unveils Promising Clinical Data for IBI354 During ASCO 2025 At the ASCO 2025 annual meeting, Innovent Biologics presented promising clinical data for IBI354, a novel anti-HER2 ADC for advanced tumors.

Innovent Biologics Unveils Promising Clinical Data for IBI354 During ASCO 2025 #China #Suzhou #Innovent #IBI354 #ASCO2025

Innovent Begins Phase 3 Trials for IBI354 in Treating Platinum-Resistant Ovarian Cancer Innovent Biologics has successfully dosed its first participant in a Phase 3 clinical trial for IBI354, targeting platinum-resistant ovarian cancer. This study is a significant step in oncology treatment.

Innovent Begins Phase 3 Trials for IBI354 in Treating Platinum-Resistant Ovarian Cancer #China #Suzhou #Innovent #IBI354 #HER2_ADC